Goldman Sachs
BTAI icon

Goldman Sachs’s BioXcel Therapeutics BTAI Stock Holding History

Goldman Sachs’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,675
Closed -$1.24M – 6091
2020
Q4 		$1.24M Buy
1,675
+237
+16% +$185K ﹤0.01% 4058
2020
Q3 		$997K Buy
+1,438
New +$1.08M ﹤0.01% 4078

Other funds holding BTAI

OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Goldman Sachs's BTAI Position: Q2 2025 in Review

Goldman Sachs sold out of BioXcel Therapeutics (BTAI) in Q2 2025, closing a stake of 24,794 shares — an estimated $50.3K sold.

Goldman Sachs first reported a position in BTAI in Q1 2018 and held it in 21 quarters. The position peaked at $10.4M in Q4 2020. 35 funds tracked by Wall St. Rank hold BTAI as of Q2 2025.

  • Goldman Sachs reported no remaining BioXcel Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 24,794 BioXcel Therapeutics shares in Q2 2025, an estimated $50.3K.
  • Goldman Sachs first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 21 quarters.
  • Goldman Sachs's BioXcel Therapeutics position peaked at $10.4M in Q4 2020.
  • 35 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.